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Abstract
Objective: To perform a network meta-analysis (NMA) to compare the long-term 
effectiveness of mindfulness-based cognitive therapy (MBCT) with available strategies for 
prevention and time to depressive relapse.
Methods: Seven electronic databases were searched up to June 2019. Studies evaluated 
MBCT for the management of depression related outcomes and follow-up assessments 
occurred at 12-months or longer.
Results: Twenty-three publications were included, 17 of which were randomised controlled 
trials (RCTs). Data from 14 RCTs including 2077 participants contributed to meta-analysis 
(MA) and NMA to assess relapse of depression and 13 RCTs with 2017 participants 
contributed to MA and NMA for time to relapse of depression. NMAs showed statistically 
significant advantages for MBCT over treatment as usual (TAU) for relapse of depression 
(RR=0.73, 95%CI 0.54 to 0.98) and for MBCT over TAU and placebo for time to relapse of 
depression (MCBT vs TAU: HR=0.57, 95%CI 0.37 to 0.88; MCBT vs placebo: HR=0.23, 
95%CI 0.08 to 0.67). Subgroup meta-analysis of relapse of depression by previous number of 
depressive episodes showed similar results between subgroups. Subgroup meta-analysis by 
the use or not of booster sessions suggests these may lead to improved effectiveness.
Conclusions: MBCT is more effective than TAU in the long-term in preventing relapse of 
depression and has statistically significant advantages over TAU and placebo for time to 
relapse of depression. No statistically significant differences were observed between MBCT 
and active treatment strategies for rate of relapse or time to relapse of depression.
Summations
Our results show that mindfulness-based cognitive therapy has advantages when compared 
to treatment as usual and placebo.
Subgroup meta-analysis based on previous number of depressive episodes showed very 
similar results for relapse of depression between the subgroups.
Booster sessions may be advantageous, but the results are uncertain due to heterogeneity 
and lack of published information of timings, frequency and attendance at booster sessions.
Limitations
The data available was limited for some of the comparisons in the meta-analysis and network 
meta-analysis and there was some heterogeneity in some of the analyses.
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Introduction
Mindfulness-based cognitive therapy (MBCT) is a pragmatic (but theoretically and 
experimentally derived) manualised treatment approach developed to address a common but 
specific clinical problem: frequent recurrence of depressive illness (1). A multi-centre 
randomised controlled trial (2) followed by a replication trial (3) provided confirmation of the 
efficacy of MBCT in significantly reducing relapse rates in recurrent depression when 
compared to treatment as usual. The evidence led to the inclusion of MBCT in the UK National 
Institute for Health and Care Excellence (NICE) guideline for depression and the 
recommendation of “mindfulness-based cognitive therapy for people who are currently well 
but have experienced three or more previous episodes of depression” p.34 (4). Subsequent 
widespread clinical employment of MBCT encouraged further research fuelling systematic 
reviews and meta-analyses (5-7) that drew supportive general conclusions regarding efficacy 
in preventing depressive relapse when compared to usual care, albeit with degrees of 
equivocation and a consensus that there remained a need for further research to resolve 
uncertainties. However, conventional pairwise meta-analyses can only compare two 
interventions at a time, cannot efficiently include data from studies with more than two 
treatment arms and can consider only direct evidence. Network meta-analysis (NMA) can 
combine direct and indirect evidence, incorporating all relevant data from studies with more 
than two treatment arms and therefore allow assessment of the relative effectiveness of MBCT 
when compared to alternative treatments.
Aim of the study
An NMA evaluating the effectiveness of MBCT has not been performed. The aim of this study 
was to compare the long-term effectiveness of MBCT with available strategies for prevention 
and time to depressive relapse.
Material and Methods
The systematic review methods followed the general principles outlined in the Centre for 
Reviews and Dissemination (CRD) guidance for conducting reviews in health care (8). This 
article is reported in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) (9). The protocol for the review was registered with 
PROSPERO as CRD42018099375.
Search strategy
Potentially eligible studies were identified by searching electronic databases and by reference 
list trawling. We searched electronic databases CINAHL, Cochrane Central Register of 
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Controlled Trials (CENTRAL) & Cochrane Database of Systematic Reviews, Embase, 
MEDLINE, PsycINFO, and Web of Science initially from inception up to 26 July 2018 and 
updated the searches up to 28 June 2019. The search strategy used for the MEDLINE 
database is presented in Supplementary material 1 of this manuscript. The MEDLINE search 
strategy was adapted to enable similar searches of the other relevant electronic databases. 
Literature search results were managed using EndNote X8.2 software.
Study selection
Titles and abstracts were screened independently by two reviewers. Those identified as 
meeting the eligibility criteria (Supplementary material 2) were retained, and all other papers 
were excluded. If sufficient detail to enable such a decision was not clearly available in the 
title or abstract, then a full text version of the paper was acquired and reviewed before a 
decision was made. Full text versions of all retained papers were obtained and screened 
independently by two reviewers. Any disagreements regarding study eligibility were resolved 
by discussion and when necessary by consultation with a third reviewer. As MBCT was 
primarily designed as an intervention for depressive illness, this review only considers studies 
which have depression related outcomes. There is no accepted definition of what period would 
constitute “long-term” so for the purpose of this review it was considered to be 1 year or longer.
Data extraction
A standardised form was used for data extraction. The following data fields were included: 
authors, year, study design, control, setting, population (incl. demographics), baseline health 
data, follow-up and drop-out rates, outcome measures used and summary statistics of results. 
Table 1 summarises the characteristics of studies included and key data extracted. Data was 
extracted by the lead reviewer and then examined for accuracy by an independent reviewer. 
Any disagreements regarding data extraction were resolved by discussion and when 
necessary by consultation with a third reviewer.
Risk of bias assessment
Risk of bias of RCTs was assessed according to the Cochrane risk of bias tool.(10) The Downs 
and Black checklist (11) was used for the assessment of non-randomised trials 
(Supplementary material 3). Risk of bias assessment was performed by one reviewer and 
checked for agreement by a second independent reviewer. Any disagreements regarding risk 
of bias assessment were resolved by discussion and when necessary by consultation with a 
third reviewer.
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Data analysis
Meta-analysis (MA) and NMA for the outcomes ‘Relapse of Depression’ (expressed as a 
pooled risk ratio (RR) and 95% confidence interval (CI)) and ‘Time to Relapse of Depression’ 
(expressed as a pooled hazard ratio (HR) and 95% CI) were conducted.
Two of the included RCTs (12, 13) had three treatment arms (MBCT and two control arms) 
which causes complexity for meta-analysis.(14) Two analysis approaches were taken to 
account for this complexity:
 Control groups were broadly categorised into three subgroups (treatment as usual 
(TAU), placebo, maintenance antidepressant medication (mADM) and other active 
controls). MAs of MBCT versus control were conducted separately by control group. 
This approach allows both of the control groups from the three-armed studies(12, 13) 
to be included within meta-analysis. An additional meta-analysis by control group 
subgroups was conducted splitting the TAU control subgroup by whether study 
eligibility required remission and being off antidepressant medication at baseline or 
whether the use of antidepressant or mood stabilisers was permitted at baseline.
 A network of MBCT and all control treatments was constructed (Figure 1) and NMA 
was also performed. This approach is the most appropriate method to take account of 
the different control treatments while also taking account of the trials with three 
treatment arms and the correlations between the pairwise treatment comparisons in 
these trials.
[Insert Figure 1 here]
Subgroup meta-analysis was performed for the outcome ‘Relapse of Depression’ according 
to the previous number of depressive episodes required for inclusion within the RCT (at least 
3 previous episodes for inclusion vs less than 3 episodes required for inclusion) and by 
whether booster sessions were used during follow-up. To allow the two RCTs (12, 13) with 
three treatment arms to be included within this subgroup meta-analysis, the results of control 
arms within the two RCTs were pooled by adding together the number of participants and 
number of events (i.e. relapses of depression) in the two control arms. These two RCTs could 
not be included within subgroup meta-analysis for ‘Time to Relapse of Depression’ as it was 
not possible to combine the published HRs for the control arms within the two RCTs; access 
to individual participant data would be required to accurately pool time-to-event data for the 
two control arms.
MAs were performed using the inverse-variance method via the metan command (15) in Stata 
version 14.1. NMA was performed under a multivariate meta-analysis framework (16) with an 
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exchangeable variance-covariance structure via the network command in Stata version 
14.1.(17) Both MA and NMA were conducted with random-effects due to anticipated 
heterogeneity between trials.
The underlying assumption of NMA is that any indirect evidence is consistent with the direct 
evidence where a comparison exists (known as the consistency assumption).(18) To 
investigate inconsistency within the NMA, direct treatment effect estimates from individual 
trials or MA were compared to treatment estimates calculated via NMA and a ‘design-by-
treatment’ inconsistency model, a method which evaluates both loop and design 
inconsistencies, particularly within multi-arm trials (19) was fitted via the network command in 
Stata version 14.1.(17)
Due to variability of outcome definitions, follow-up times and variability of reported results for 
other outcomes within the RCTs, it was not possible to combine results for other outcomes in 
MA or NMA. Results for other outcomes reported in the RCTs and results of the non-
randomised studies are summarised narratively.
Results
Searches identified a total of 2092 publications. Removal of duplicates and application of 
eligibility criteria resulted in 23 studies included in the systematic review (Figure 2). The 
publications by Huijbers et al (20, 21) and Spinhoven et al (22) were part of the Dutch 
multicentre MOMENT study involving a total of 317 participants; publications by Michalak et 
al (23, 24) used data from the same German group of 29 participants; and publications by 
Shallcross et al (25, 26) were sequential long-term follow-up studies of the same group of 92 
participants.
[Insert Figure 2 here]
Study characteristics
Seventeen of the 23 studies were RCTs (Table 1). Four of the RCTs used TAU,(2, 3, 27, 28) 
and two used waiting list as a control.(29, 30) TAU was defined as participants being told to 
seek help from their family doctor of other sources as they normally would, should they 
encounter symptomatic deterioration or other difficulties over the course of the study (2, 3, 27) 
or weekly handouts.(28) In a study with two control groups, TAU was not specified but the 
therapist informed participants they should seek treatment as needed from their usual health 
care provider throughout the trial duration.(13) Two of the RCTs employed cognitive behaviour 
therapy (CBT)(31) or cognitive therapy (CT)(32) as a comparator intervention, two RCTs used 
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an active control condition (ACC)(25, 26) and one used depression relapse active monitoring 
(DRAM).(33) The comparator group in three RCTs was mAMD.(20, 34, 35) The comparator 
intervention in one RCT was MBCT in addition to mADM.(21) Two RCTs included two control 
groups; one compared MBCT to mAMD and to placebo pills with clinical management (12), 
and one RCT compared MBCT to cognitive psychological education (CPE) and to TAU (13). 
Eight of the 17 RCTs reported that booster sessions were provided. Three RCTs indicated 
that booster sessions were provided at regular three-month intervals up to 12 months follow-
up.(27, 34, 35) The timings and frequency of booster sessions varied in the remaining 
studies.(2, 3, 12, 13, 33) Two studies stated that booster sessions were optional.(12, 33) The 
proportion of participants that attended booster sessions was not reported in any of the 
included studies. Only one of the RCTs clearly reports in the discussion that booster sessions 
were not provided.(26)
Eight of the 23 studies employed a follow-up period of one year. The longest follow-up in the 
RCTs included was 26 months (26, 33) and for the non-RCTs the longest mean follow-up was 
49 months (36).
[Insert Table 1 here]
Participant demographics
The studies recruited participants who had a recurrent depressive disorder and were either in 
remission or had residual depressive symptoms. For the majority of studies (12, 13, 20-27, 
29, 30, 32), criteria for depression was based on the Diagnostic and Statistical Manual of 
Mental Disorders-Fourth Edition (DSM-IV)(37) and assessed using the Structured Clinical 
Interview for DSM-IV (SCID) Axis 1 Disorders (38). Some studies mentioned using DSM-IV 
criteria (3, 34, 35, 39, 40), DSM-IV criteria on the computerised version of the Composite 
International Diagnostic Interview (CIDI-AUTO) (31), CIDI 2.1 (33) or DSM-III-R (2) to 
diagnose depression but did not specify how it was assessed. The criteria were unclear in one 
study (36). The population in one study (28) comprised people with bipolar affective disorder 
based on DSM-IV criteria (unclear how assessed), however, the primary outcome of this study 
was time to recurrence of a major episode including a depressive episode and also assessed 
the number of depressive relapses. In all but one study the majority of participants were female 
(range 58% to 80%). The mean age of participants in each study ranged from 35 to 54 years.
Quality assessment
Details of the risk of bias assessment for included RCTs and quality assessment of non-RCTs 
are presented in Supplementary material 4. All studies were judged to have low or unclear risk 
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of bias for the domains random sequence generation, allocation concealment, selective 
reporting or other bias. Participant blinding is not possible with a group-delivered 
psychotherapy such as MBCT, therefore all studies were judged to have a high risk of bias for 
the blinding of participants and/ or personnel domain. Three studies were judged to have a 
high risk of bias for the blinding of outcome assessors domain as the research assistants 
conducting the assessments were not blind to the intervention delivered.(20, 21, 29) One study 
was judged to have a high risk of bias for the incomplete outcome data domain as only data 
from participants that completed the trial were included in the analysis.(31)
Relapse of depression
Rate of relapse or time to relapse during the follow-up period was the primary outcome 
measure in 15 RCTs and change in depressive symptoms the primary outcome measure in 2 
RCTs. Studies in which the primary outcome measure was relapse, this was assessed based 
on DSM-IV criteria for major depressive episode using the depression module of the SCID 
(38) in 12 of the publications (12, 13, 20, 21, 25-28, 30, 32, 34, 35) or Structured Clinical 
Interview for DSM–III–R (41) in two publications (2, 3). One study (33) assessed relapse based 
on CIDI 2.1 12-month version depression module (42).
Meta-analysis and network meta-analysis results
Results of 14 RCTs (2, 3, 12, 13, 20, 21, 26-28, 30, 32-35) including 2077 participants could 
be combined in MA and NMA for ‘relapse of depression’ and results of 13 RCTs (2, 3, 12, 13, 
20, 21, 26, 28, 30, 32-35) including 2017 participants could be combined in MA and NMA for 
‘time to relapse of depression’. The data extracted which has contributed to the analysis is 
presented in Supplementary material 5. Six RCTs compared MBCT to TAU, four RCTs 
compared MBCT to mADM and one RCT compared MBCT to each of placebo, ACC, CPE, 
CT, DRAM or MBCT added to mADM.
Results of MA and NMA are presented in Table 2 for MBCT compared to all control treatments. 
MA results by control group are shown in Figure 3A and 3B and NMA results are shown in 
Figure 3C and Figure 3D.
[Insert Table 2 here]
[Insert Figure 3 here]
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Both MA and NMA showed a statistically significant advantage for MBCT over TAU for relapse 
of depression (meta-analysis RR from MA 0.72, 95% CI (0.55 to 0.93); network meta-analysis 
RR 0.73, 95% CI (0.54 to 0.98), Table 2).
Both MA and NMA also showed a statistically significant advantage for MBCT over both TAU 
and placebo for time to relapse of depression (MCBT vs TAU: HR from MA 0.52, 95% CI (0.30 
to 0.90); HR from NMA 0.57, 95% CI (0.37 to 0.88); MCBT vs placebo: HR from MA 0.26, 95% 
CI (0.09 to 0.79); HR from NMA 0.23, 95% CI (0.08 to 0.67, Table 2).
MA with TAU control subgroups split according to study eligibility criteria showed a statistically 
significant advantage for MBCT over TAU for relapse of depression (RR 0.73, 95% CI (0.59 
to 0.90) but not for time to relapse of depression, where remission was required at baseline. 
There were no differences between MBCT and TAU for relapse or time to relapse of 
depression where antidepressant medication or mood stabilisers were permitted at baseline, 
however the results of the two studies of MBCT compared to TAU permitting antidepressant 
medication or mood stabilisers showed substantially different results (Supplementary material 
6).
No differences between MBCT and mADM, ACC, CPE, CT or DRAM were shown in MA or 
NMA for either outcome (Table 2). There were also no differences for either outcome in MA 
for MBCT vs other active controls considered together (Figure 3A and Figure 3B).
A statistically significant advantage for MCBT added to mADM was shown over MCBT alone 
in MA for both outcomes (relapse of depression RR 1.39 95% CI (1.05 to 1.83) and time to 
relapse of depression HR 1.59 95% CI (1.09 to 2.31), Table 2) but this advantage was not 
shown within NMA (Table 2, Figure 3C and Figure 3D).
Overall, results of MA and NMA (except for the comparison of MCBT added to mADM was 
shown over MCBT alone) were very similar and reached the same conclusions (Table 2). 
Heterogeneity was observed in MA, with I2 values of around 30% to 60% observed within the 
MAs of MBCT compared to TAU or placebo and MBCT compared to other active controls 
(Figure 3A and Figure 3B). Some HRs extracted from published RCT reports for the outcome 
‘Time to Relapse of Depression’ reflected only the treatment comparison of MBCT versus the 
control while other HRs were also adjusted for other factors such as number of depressive 
episodes and severity of depression at baseline. This may have been a source of 
heterogeneity. CIs of results from NMA were generally wider than CIs of results from MA which 
likely reflects the heterogeneity present within the network as well as the sparse data, often 
Page 9 of 26 Acta Psychiatrica Scandinavica submitted manuscript
10
from only a single study within some links of the network, resulting in wider CIs from conducting 
a random-effects NMA. Despite the different conclusions which could be drawn for the 
comparison of MCBT added to mADM was shown over MCBT alone from direct evidence (i.e. 
the MA) and from NMA, there was no evidence of inconsistency present according to the 
‘design-by-treatment’ inconsistency model (p-value = 0.768 for NMA of relapse of depression 
and p-value=0.546 for NMA of time to relapse of depression).
Subgroup meta-analysis of relapse of depression and time to relapse of depression by the 
previous number of depressive episodes (i.e. less than three previous episodes or at least 
three previous episodes) required for inclusion within the RCT showed very similar results and 
no difference in conclusions between the subgroups (Supplementary material 7).
Subgroup meta-analysis showed a statistically significant advantage for MBCT over control 
where booster sessions were used during follow-up (RR for relapse of depression 0.80, 95% 
CI 0.71 to 0.89 and HR for time to relapse of depression 0.65, 95% CI 0.47 to 0.91). No 
difference was shown between MBCT and control where booster sessions were not used 
during follow-up. However, substantial heterogeneity between the studies without booster 
sessions was present and confidence intervals were wide (Supplementary material 8), 
therefore it is uncertain whether the use of booster sessions influences the treatment effect of 
MBCT over control. Further uncertainty stems from the limited detail provided in the included 
studies on the timing of booster sessions, frequency and attendance (i.e. the proportion of 
participants who actually received the booster sessions).
Two non-RCTs that included depressive relapse as an outcome measure observed that post-
MBCT mindfulness scores (23) and levels of rumination (24) were predictors of depressive 
relapse.
Other outcome measures
One RCT (involving 130 participants) that assessed depressive symptoms as a primary 
outcome (rather than depressive relapse) showed a significant benefit of MBCT compared to 
waiting list (29). One other RCT (involving 69 participants) assessing depressive symptoms 
as a primary outcome showed that both MBCT and CBT significantly improved symptoms, but 
that there was no significant difference between the two interventions (31). Statistically 
significant improvements in depressive symptoms and quality of life (QoL) following MBCT 
were observed in RCTs comparing MBCT with TAU (30) and mADM.(34) No statistically 
significant differences were observed for depressive symptoms or QoL in other RCTs with an 
active control (i.e. mADM and ACC).(20, 21, 26, 35) One RCT observed that patients receiving 
Page 10 of 26Acta Psychiatrica Scandinavica submitted manuscript
11
MBCT had statistically significantly fewer days with a major depressive episode than those in 
the active monitoring control group.(33)
Two non-RCTs observed statistically significant improvements in depressive symptoms 
between baseline post-treatment (36) and up to follow-ups of 13 to 34 months.(39) One study 
observed statistically significant improvements before and after intervention for ruminative 
thinking, mindfulness and state and trait anxiety and no differences between post-treatment 
and average follow-up of 49 months.(36) Statistically significant improvements in ruminative 
thinking,(40) mindfulness scores and personality facets were also observed.(22)
Discussion
MA and NMA shows that MBCT is more effective than TAU in preventing relapse of depression 
and has statistically significant advantage over TAU and placebo for time to relapse of 
depression. Booster-sessions at regular intervals may result in higher effectiveness of MBCT 
to prevent relapse of depression and delay time to relapse in the long-term. Current 
recommendations are for four follow-up sessions in the 12 months after the end of treatment 
(4). The use of booster sessions, timing, frequency and attendance should be clearly reported.
The first two major studies of MBCT found positive benefits for reducing risk of relapse, but 
suggested this was limited to those patients who had suffered three or more previous episodes 
(2, 3). Indeed, the results of those studies also suggested a tendency to increased risk of 
relapse following MBCT in participants who had a history of fewer than 3 previous episodes. 
However, our subgroup MA based on previous number of depressive episodes found similar 
results between those with at least 3 previous episodes and those with less than 3 previous 
episodes. It is a clear point of NICE guidance that MBCT is only recommended for patients 
who have experienced 3 or more previous episodes of depression. Implications of the findings 
of our review and further analysis accounting for previous episodes of depression should be 
considered in future research and guidance development.
Our results are similar to a meta-analysis that evaluated the effectiveness of all psychological 
interventions to prevent relapse compared with TAU (RR 0.66; 95% CI 0.53 to 0.82) and 
mADM (RR 0.80; 95% CI 0.60 to 1.08).(43) An individual patient data (IPD) meta-analysis 
observed that MBCT resulted in a reduced risk of depressive relapse compared with those 
who did not receive MBCT (HR 0.69; 95% CI 0.58 to 0.82), with any active treatment (HR 
0.79; 95% CI 0.64 to 0.97) and with mADM (HR 0.77; 95% CI 0.60 to 0.98).(6) IPD meta-
analysis allows for more accuracy in the estimation of the effect of MBCT, while our estimates 
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are based on the results presented within the included studies. However, the IPD meta-
analysis is limited by the unavailability of study data from Meadows et al.(33) This study was 
included in our quantitative synthesis as well as the study by Perich et al.(28) which evaluates 
relapse and time to relapse of depression in people with bipolar disorder. Excluding the study 
by Perich et al. from the pooled analysis within a sensitivity analysis did not change the 
conclusions (i.e. MBCT would continue to be more effective than TAU, sensitivity analysis 
results available from the authors on request).
Consistent with the personalised medicine approach being adopted in healthcare services 
(44), research also appears to be trying to identify other subgroups that may specifically 
benefit from MBCT, with those who have experienced childhood adversity and other early life 
trauma identified as one such group (13). It is likely that future research will continue this trend, 
but there will remain an inherent danger of “data-dredging” and type-1 errors (45) that should 
be minimised by high quality and transparent study design and rigorous methodology (46).
Further consideration of the enduring effects of TAU on depressive relapse leads to reflection 
upon those studies in this review that compare MBCT with another specific active intervention 
as there are practical clinical implications. In all those studies that compared MBCT to 
antidepressant medication no overall significant advantage to MBCT was demonstrated (12, 
20-22, 35) and no advantage was observed by adding MBCT to antidepressant medication 
(20). However, long term follow-up studies also show that both MBCT and antidepressants 
can each confer enduring positive effects and thus MBCT may offer an alternative to 
medication in some cases (12, 34, 35). It should also be recognised that withdrawal of 
maintenance antidepressants may increase depressive relapse (21). It has been suggested 
that the key components responsible for part of the effects of psychotherapies for adult 
depression cannot be dismantled but may be caused by non-specific factors common to all 
therapies (47).
A driver to the original development of MBCT was the recognition that CBT, whilst effective 
for acute depressive episodes it did not reliably reduce the rate of future relapse (1). 
Subsequent studies however, have reported that the acute phase of CBT is effective at 
reducing the risk of depressive relapse.(48-51) We observed no statistically significant 
differences between MBCT and CBT in reducing rate or time to relapse. It is of paramount 
importance to consider the issue of patient choice and involvement in the decisions about 
which treatment options they choose. This is a progressive issue and active debate for 
conditions such as psychosis (52, 53). Patient choice can result in an improvement in 
adherence to treatments and consequently in effectiveness and cost-effectiveness of 
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treatments.(54) This is of particular relevance for MBCT as recent systematic review of 
economic evaluations of acceptance and mindfulness-based interventions reported that there 
is still considerable uncertainty surrounding the cost-effectiveness of MBCT for management 
of mental health conditions including recurrent depression (55).
Strengths and limitations
Our review followed best practice recommendations for systematic reviews.(8, 9) To our 
knowledge this systematic review reports the first NMA evaluating the long-term effectiveness 
of MBCT compared to control treatments in preventing relapse and time to relapse of 
depression. The focus of the review was MBCT when employed for the management of 
depressive symptoms rather than treatments of depression in general; as such, an inclusion 
criterion was that studies had an MCBT group. Moreover, the aim of the review was to 
investigate how MBCT performed compared to control treatments rather than to rank all 
available treatments, which is often evaluated within an NMA framework.
The data available was limited for some of the comparisons in the meta-analysis and NMA 
and there was some heterogeneity in some of the analyses. The CIDI was used in one of the 
studies included in the quantitative synthesis.(33) It should be noted that the CIDI was 
developed for epidemiological studies as a screening tool but does not represent a clinical 
diagnosis. It is possible that the study inclusion criteria that required publications to be in 
English and to be published in peer-reviewed journals may lead to selection bias and may 
have caused some relevant studies to be overlooked.
In conclusion, we found that MBCT is more effective than TAU in the long-term in preventing 
relapse of depression and has statistically significant advantages over TAU and placebo for 
time to relapse of depression. No statistically significant differences were observed between 
MBCT and alternative strategies evaluated (i.e. mADM, ACC, CPE, CT or DRAM) both for 
rate of relapse or time to relapse of depression. Subgroup meta-analysis by number of 
previous episodes of depression showed very similar results. Use of booster sessions may 
result in improved outcomes and its use, timings, frequency and attendance should be clearly 
reported.
Page 13 of 26 Acta Psychiatrica Scandinavica submitted manuscript
14
Data availability statement
The data that supports the findings of this study are available in the supplementary material 
of this article
Figure legends
Figure 1. Network plot of MBCT and all control treatments
Figure 2. PRISMA flow chart
Figure 3. Meta-analysis and network meta-analysis of relapse of depression and time to 
relapse of depression comparing MBCT to control
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Figure 1. Network plot of MBCT and all control treatments 
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Figure 2. PRISMA flow chart 
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Meta-analysis and network meta-analysis of relapse of depression and time to relapse of depression 
comparing MBCT to control 
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Table 1 Characteristics of studies included in the systematic review
Author (year) and 
setting
Number in analysis, sex, mean 
age






MBCT (n=31); control (n=29)
74% female
46 years
Recurrent depressive illness 
in remission
TAU 14 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence
Depression severity (MADRS)
Severity of depressive symptoms (BDI-II)
Mindfulness practice (MBCT group only)
(-) p=0.58
 p=0.006
NR (only assessed at baseline)
NR (only assessed at baseline)
(-) between relapsers and non-relapsers
Farb (2018)(32)
Canada
MBCT (n=82); control (n=84)
66% female
40 years
Major depressive disorder in 
remission
CT 24 months Relapse or recurrence (SCID for DSM-IV)






















MBCT (n=40); control (n=47)
81% female
45 years
Recurrent depressive illness 
in remission
Waiting list 14 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence
Depressive symptoms (HRSD)
Severity of depressive symptoms (BDI-II)







POMS depressive  p<0.01
POMS angry (-)
POMS tired (-)




MBCT (n=33); control (n=35)
72% female
52 years
Major depressive disorder in 
remission
mADM 15 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence
Severity of depressive symptoms (IDS-C)







MBCT (n=128); control (n=121)
67% female
50 years




15 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence
Severity of depressive symptoms (IDS-C)
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Kuyken (2008)(34)
UK
MBCT (n=61); control (n=62)
77% female
49 years
Recurrent depressive illness 
in remission
mADM 15 months Time to relapse or recurrence
Relapse or recurrence (SCID for DSM-IV)
Depressive symptoms (HRSD)
Severity of depressive symptoms (BDI-II)





WHOQOL-BREF physical  p=0.04




MBCT (n=212); control (n=212)
77% female
49 years
Recurrent depressive illness 
in remission
mADM 24 months Time to relapse or recurrence
Relapse or recurrence (SCID for DSM-IV)
Depression free days (SCID)
Depressive symptoms (GRID-HAMD)
Severity of depressive symptoms (BDI-II)
Psychiatric comorbidities (SCID)
Medical comorbidities (MSCL)













MBCT (n=36); control (n=37)
76% female
44 years
Depressive illness in 
remission
TAU 12 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence
Dysfunctional parenting (MOPS)
 3 episodes p=0.002; 2 episodes p=0.23
(-) p=0.17
MOPS indifference  p<0.001





MBCT (n=19); control (n=26)
64% female
46 years
Major depressive disorder CBT 12 months Severity of depressive symptoms (BDI-II)
Severity of anxiety symptoms (BAI)






MBCT (n=86); control (n=91)
81% female
48 years
Residual depressive illness DRAM 26 months Days in MDE
Relapse or recurrence (CIDI)






MBCT (n=48); control (n=47)
65% female
42 years
Bipolar affective disorder TAU 12 months Time to relapse or recurrence
Relapse or recurrence (SCID for DSM-IV)
Symptoms of mania (YMRS)
Depression severity (MADRS)
Depression, anxiety and stress (DASS)
State and trait anxiety (STAI)
Dysfunctional beliefs (DAS-24)






STAI-state anxiety  p=0.048
STAI-trait anxiety (-) p=0.075
(-)
(-)
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Trait mindfulness (MAAS) (-)
Segal (2010) (12)
Canada











Time to relapse or recurrence









MBCT (n=46); control (n=46)
76% female
35 years
Depressive illness in 
remission
ACC 14 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence








(as Shallcross 2015 (25)) Depressive illness in 
remission
ACC 26 months Relapse or recurrence (SCID for DSM-IV)
Time to relapse or recurrence








MBCT (n=55); control (n=50)
76% female
43 years
Recurrent depressive illness 
in remission
TAU 12 months Relapse or recurrence (SCID for DSM-III-R)













12 months Time to relapse or recurrence









Major depressive disorder, 
bipolar affective disorder 
depressed phase, or 
dysthymia
- 13 to 34 
months











Recurrent depressive illness 
in remission
- 12 months Depressive symptoms (HRSD)
Severity of depressive symptoms (BDI)
Trait mindfulness (MAAS)
Relapse or recurrence (SCID for DSM-IV)
Mindfulness predicted the risk of 
relapse/recurrence after controlling for 




(as Michalak (2008) (23)) Recurrent depressive illness 
in remission
- 12 months Ruminative thinking (RSS)
Depressive symptoms (HRSD)
Relapse or recurrence (SCID for DSM-IV)
Post-treatment levels of rumination 
predicted the risk of relapse of major 
depressive disorder in the 12-month 
follow-up period even after controlling for 
numbers of previous episodes and residual 
depressive symptoms






Depressive illness in 
remission
- 49 months Severity of depressive symptoms (BDI-II)
Ruminative thinking (RSS)
Mindfulness (FMI)
State and trait anxiety (STAI)
 p<0.0001 pre-post (-) p=0.71 post-fu
 p=0.004 pre-post (-) p=0.12 post-fu
 p=0.023 pre-post (-) p=0.94 post-fu
STAI-state  pre-post (-) post-fu






Recurrent depressive illness 
in remission
- 15 months Mindfulness (FFMQ)
Personality facets (NEO PI-R)
 p<0.001 (all subscales)
NEO PI-R neuroticism  p<0.001
NEO PI-R extraversion  p=0.03
NEO PI-R conscientiousness  p<0.01
NEO PI-R agreeableness (-) p=0.12
NEO PI-R openness to experience (-) 
p=0.43






Recurrent depressive illness 
in remission and recurrent 
depressive illness
- 15 months Severity of depressive symptoms (BDI)
Ruminative thinking (RSS)
Mindfulness (KIMS)





ACC=active control condition, BAI=Beck Anxiety Inventory; BDI-II=Beck Depression Inventory ll; CBT=cognitive behaviour therapy; CIDI=Composite International Diagnostic Interview; CPE=cognitive psychological 
education; CT=cognitive therapy; DAS=Dysfunctional Attitudes Scale; DASS=Depression Anxiety Stress Scales; DRAM=depression relapse active monitoring; DSM-IV=Diagnostic and Statistical Manual of Mental 
Disorders-Fourth Edition; EQ=Experiences Questionnaire; FMI=Freiburg Mindfulness Inventory; gCBT=group cognitive behaviour therapy; GRID-HAMD=GRID Hamilton Rating Scale for Depression; HRSD=Hamilton 
Rating Scale for Depression; IDS=Inventory of Depressive Symptoms; KIMS=Kentucky Inventory of Mindfulness; mADM=maintenance antidepressant medication; MADRS=Montgomery-Asberg Depression Rating Scale; 
MAAS=Mindful Attention Awareness Scale; MBCT=mindfulness based cognitive therapy; MDE=major depressive episode; MOPS=Measure of Parenting Style; MSCL=Medical Symptom Checklist; NEO PI-R=NEO 
Personality Inventory–Revised; NR=not reported; POMS=Profile of Moods Scale; QIDS=Quick Inventory of Depressive Symptomatology; QLDS=Quality of Life in Depression Scale; RSQ=Response Style Questionnaire; 
RSS=Rumination on Sadness Scale; SCID=Structured Clinical Interview; SOFAS=Social and Occupational Functioning Scale; STAI=State/Trait Anxiety Inventory; SWL=Satisfaction With Life Scale; TAU=treatment as usual; 
WHOQOL=World Health Organization Quality of Life; YMRS=Young Mania Rating Scale
* Replication trial of studies (2) & (3)
(-) no statistically significant differences between groups (RCTs) or no difference with MBCT (non-RCTs)
 statistically significant improvements for MBCT group (RCTs) or statistically significant improvement with MBCT (non-RCTs)
 statistically significant improvements for control group (RCTs) or statistically significant deterioration with MBCT (non-RCTs)
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Table 2 Results of meta-analysis and network meta-analysis for outcomes relapse of depression and time to relapse of depression: MBCT compared to 
control treatments
Relapse of depression: RR (95% CI)a Time to relapse of depression: HR (95% CI)a
Control group Number of participants (number of studies) Direct evidenceb NMA results Direct evidenceb NMA results
Placebo 54 (1)c 0.64 (0.37 to 1.11) 0.66 (0.30 to 1.47) 0.26 (0.09 to 0.79) 0.23 (0.08 to 0.67)
TAU 584 (6)d 0.72 (0.55 to 0.93) 0.73 (0.54 to 0.98) 0.52 (0.30 to 0.90) 0.57 (0.37 to 0.88)
DRAM 177 (1)e 0.83 (0.61 to 1.11) 0.83 (0.50 to 1.36) 0.71 (0.47 to 1.07) 0.71 (0.38 to 1.31)
CPE 218 (1)c 0.93 (0.70 to 1.22) 0.87 (0.56 to 1.34) 0.83 (0.56 to 1.24) 0.80 (0.41 to 1.54)
mADM 673 (4) 0.90 (0.76 to 1.06) 0.90 (0.69 to 1.18) 0.83 (0.66 to 1.05) 0.81 (0.56 to 1.17)
ACC 92 (1) 0.96 (0.63 to 1.45) 0.96 (0.47 to 1.95) 0.76 (0.31 to 1.89) 0.76 (0.27 to 2.11)
CT 166 (1) 1.02 (0.57 to 1.83) 1.02 (0.50 to 2.11) 1.16 (0.60 to 2.25) 1.16 (0.52 to 2.60)
MBCT + mADM 249 (1) 1.39 (1.05 to 1.83) 1.39 (0.89 to 2.17) 1.59 (1.09 to 2.31) 1.59 (0.88 to 2.88)
Results in bold are statistically significant. There was no evidence of inconsistency present within either NMA according to the ‘design-by-treatment’ inconsistency model (p-
value = 0.768 for NMA of relapse of depression and p-value=0.546 for NMA of time to relapse of depression).
ACC = active control condition; CI = confidence intervals; CPE = Cognitive Psychological Education; CT = cognitive therapy; DRAM = depression relapse active monitoring; HR 
= hazard ratio; mADM = maintenance antidepressant medication; MBCT = mindfulness based cognitive therapy; NMA = network meta-analysis; TAU = treatment as usual
a. RR or HR less than 1 indicates an advantage to MBCT over the control
b. Direct evidence is the study specific RR and 95% CI where only one RCT included the control (Placebo, DRAM, CPE, ACC, CT and MBCT + mADM) and from meta-
analysis were more than one study included the control (TAU and mADM)
c. Within one study (13) of MCBT compared to CPE compared to Placebo, a HR for time to relapse of depression for CPE compared to Placebo was not reported for 
all participants. To allow NMA to be conducted, a HR for participants with low childhood trauma questionnaire (CTQ) scores was extracted for CPE vs TAU. 
Sensitivity analysis was conducted using a HR for participants with high CTQ scores; NMA results were very similar and conclusions unchanged (results available on 
request)
d. A HR could not be extracted or estimated for one study comparing MBCT and TAU,(27) therefore the analyses for ‘time to relapse of depression’ are based on 524 
participants from 5 studies for MBCT vs TAU.
e. A HR was not reported within the trial publication,(33) but could be estimated indirectly using the number of events and log-rank p value according to the 
methods of Tierney et al.(43) 
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